SCHEMBL3907168

SCHEMBL3907168

Cc1ccccc1C(=O)NC(c1ccccc1)C(C)(C)N(C)C

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 1/20 0.45
HPGD P15428 3/20 0.45
LMNA P02545 5/20 0.44
ALDH1A1 P00352 4/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
THRB P10828 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
ALOX12 P18054 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ABCB1 P08183 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902328 0.91 UTS2R (0.46) UTS2RHPGDLMNAALDH1A1CYP1A2
SCHEMBL3901138 0.89 UTS2R (0.41) UTS2RHPGDLMNAALDH1A1KDM4E
SCHEMBL3913612 0.87 UTS2R (0.46) UTS2RLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL3902998 0.87 POLB (0.50) UTS2RHPGDLMNAALDH1A1SMN1; SMN2
SCHEMBL3907148 0.86 SLC6A9 (0.47) UTS2RLMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL3903926 0.85 LMNA (0.40) UTS2RHPGDLMNAALDH1A1L3MBTL1
SCHEMBL3901053 0.85 GPR139 (0.49) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3905248 0.85 KMT2A (0.44) HPGDLMNAALDH1A1KDM4EHSD17B10
SCHEMBL3903439 0.85 ALDH1A1 (0.44) HPGDLMNAALDH1A1KDM4EHSD17B10
SCHEMBL3906053 0.85 ALDH1A1 (0.57) HPGDLMNAALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed
WO-2006067417-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 UTS2R 3095/4885HPGD 664/4885LMNA 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.